Home
Watchlist
News
Signals
Picks
DJI
+0.77%
SPX
+0.83%
IXIC
+0.98%
FTSE
+0.42%
N225
+0.82%
AXJO
+0.47%
Log In
Get Started
Home
Watchlist
News
Signals
Picks
Stocks
Add to Watchlist
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.
Company
About Us
Careers
Blog
News
Help & Support
Help Center
Contact Us
Pro Support
Legal
Privacy Policy
Terms of Use
Instagram
YouTube
© 2024 Cashu PTY LTD.
Signals
RVNC
Revance Therapeutics
6 months ago
RVNC has been in the news 500% more than usual
0.00%
📡️ Health Care
RVNC
Revance Therapeutics
7 months ago
Analysts think RVNC stock price could increase by 68%
0.00%
📡️ Health Care
RVNC
Revance Therapeutics
8 months ago
RVNC has been in the news 1500% more than usual
7.20%
📡️ Health Care
RVNC
Revance Therapeutics
8 months ago
Analysts think RVNC stock price could increase by 109%
19.16%
📡️ Health Care
RVNC
Revance Therapeutics
11 months ago
RVNC is now overvalued and could go down -50%
-21.02%
📡️ Health Care
RVNC
Revance Therapeutics Inc
about 1 year ago
Analysts think RVNC stock price could increase by 3%
-18.15%
📡️ Health Care
RVNC
Revance Therapeutics Inc
about 1 year ago
RVNC has been in the news 643% more than usual
-0.23%
📡️ Health Care
RVNC
Revance Therapeutics
about 1 year ago
RVNC beat EPS expectations by 33.41%
0.00%
📡️ Health Care
RVNC
Revance Therapeutics Inc
about 1 year ago
Analysts think RVNC stock price could increase by 203%
77.43%
📡️ Health Care
RVNC
Revance Therapeutics Inc
about 1 year ago
RVNC has been granted a new patent
60.47%
📡️ Health Care
RVNC
Revance Therapeutics Inc
about 1 year ago
RVNC has been granted a new patent
60.47%
📡️ Health Care
RVNC
Revance Therapeutics Inc
about 1 year ago
RVNC has been granted a new patent
60.47%
📡️ Health Care
Join our newsletter to keep up to date with us!
Sign Up
Stocks
Health Care
rvnc
Add to Watchlist
Revance Therapeutics
NASDAQ: RVNC
0.00 (0.00%)
3.65
USD
At close at Sep 04, 13:26 UTC
Summary
News
Signals
Benchmarks
Financials